Open AccessContinuous venovenous hemodiafiltration in the treatment of newborns with an inborn metabolic disease: a single center experience
Author(s) -
Hasan Akduman,
Emel Okulu,
Fatma Tuba Eminoğlu,
Tanıl Kendirli,
Gaffari Tunç,
Ebru Azapağası,
Oktay Perk,
ÖMER EREDERE,
Begüm Atasay,
Saadet Arsan
Publication year - 2019
Publication title -
turkish journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.277
H-Index - 27
eISSN - 1303-6165
pISSN - 1300-0144
DOI - 10.3906/sag-1811-8
Subject(s) - medicine , methylmalonic acidemia , maple syrup urine disease , renal replacement therapy , metabolic acidosis , pediatrics , anesthesia , biochemistry , chemistry , leucine , amino acid
Most inborn metabolic diseases are diagnosed during the neonatal period. The accumulation of toxic metabolites may cause acute metabolic crisis with long-term neurological dysfunction and death. Renal replacement therapy (RRT) modalities allow the efficient removal of toxic metabolites. In this study, we reviewed our experience with continuous venovenous hemodiafiltration (CVVHDF) as RRT for newborns with an inborn metabolic disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom